Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTRuchi GuptaThu, July 2, 2026 at 6:35 PM GMT+2 4 min readGloved hands holding a stethoscope up to a piggy bank by ink drop via Adobe StockHaleon plc (HLN) is one of the world's largest consumer healthcare companies, formed from the combined consumer health divisions of GSK (GSK), Pfizer (PFE), and Novartis (NVS), and went public in July 2022. Haleon operates across six major therapeutic categories: oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health, and therapeutic skin health.Its iconic brand portfolio includes Sensodyne, Advil, Centrum, Panadol, Voltaren, and Theraflu, spanning markets across North America, EMEA, Latin America, and Asia Pacific, making it a go-to name in the everyday wellness and self-care space.More News from BarchartCEO Phong Le Bought 11,000 Shares of MicroStrategy Preferred Stock as STRC Hit All-Time LowsAnalysts at UBS Say Advanced Micro Devices Stock Could Rally to $670Cathie Wood Bets Big on Cerebras and Palantir Stocks After Sharp PullbackMarkets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.Haleon Stock PerformanceHLN shares are trading well below the 52-week high of $11.28, reflecting a meaningful pullback from peak levels amid investor concerns over top-line softness and macroeconomic headwinds weighing on consumer spending. The stock's 52-week low stands at $8.65, with a market capitalization of approximately $41.44 billion.Compared to the S&P 500 Consumer Staples Index ($SRCS), which has broadly held up as a defensive play in 2026, HLN has underperformed its sector peers, dragged down by cold and flu season weakness and sluggish North American volumes, despite strong margin improvement and oral health momentum.www.barchart.comHaleon Posts Mixed ResultsHaleon reported full-year 2025 revenue of £11.0 billion with 3.0% organic growth, falling short of its stated medium-term guidance range of 4-6%. The revenue miss was primarily driven by a weak cold and flu season and low consumer confidence in North America, with analysts having penciled in growth closer to 3.5% for the year. On the earnings front, however, Haleon surprised to the upside: the company reported $0.129 in earnings per share, beating the consensus estimate of $0.124 by $0.005.Despite the top-line shortfall, Haleon delivered adjusted operating profit growth of 10.5% and expanded gross margins by 220 basis points, significantly exceeding its annual target of 50-80 basis points, with adjusted gross profit margins reaching 65.2%. Oral Health led the portfolio with 7.9% growth to £3.46 billion, benefiting from innovation and premiumization initiatives, while Asia-Pacific emerged as the regional growth leader with 5.2% organic revenue growth. Pain Relief and VMS delivered steady contributions, while Respiratory Health declined due to the muted cold and flu season.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info